Related Experiment Videos
Immunostimulatory DNA is a potent mucosal adjuvant
A A Horner1, A Ronaghy, P M Cheng
1Department of Medicine, and The Sam and Rose Stein Institute for Aging, University of California at San Diego, 9500 Gilman Drive, La Jolla, California, 92093-0663, USA. aahorn@aol.com
Cellular Immunology
|November 25, 1998
Summary
Intranasal delivery of immunostimulatory sequence oligodeoxynucleotides (ISS-ODN) with antigens effectively induces mucosal and systemic immune responses. This novel vaccine approach promotes Th1-biased immunity, showing promise for mucosal pathogen vaccines.
Area of Science:
- Immunology
- Vaccinology
- Molecular Biology
Background:
- Proteins delivered to mucosal surfaces often fail to elicit robust immune responses.
- Effective adjuvants are crucial for developing vaccines against mucosal pathogens.
Purpose of the Study:
- To evaluate immunostimulatory sequence oligodeoxynucleotides (ISS-ODN) as an adjuvant for intranasal antigen delivery.
- To compare the immune responses induced by ISS-ODN with those induced by cholera toxin (CT).
Main Methods:
- Coadministration of a model antigen (beta-galactosidase, beta-gal) with ISS-ODN or CT via intranasal (i.n.) and intradermal (i.d.) routes.
- Assessment of mucosal IgA responses and systemic Th1/Th2-biased immune responses, including cytotoxic T lymphocyte (CTL) activity.
Main Results:
- Intranasal coadministration of beta-gal with ISS-ODN induced mucosal IgA responses comparable to those with CT.
- Beta-gal/ISS-ODN induced Th1-biased systemic immunity with high CTL activity, unlike the Th2-biased response with poor CTL activity induced by beta-gal/CT.
- ISS-ODN demonstrated effective adjuvant activity for both mucosal and systemic immunity via i.n. delivery.
Conclusions:
- Intranasal delivery of ISS-ODN is a potent adjuvant for inducing Th1-biased mucosal and systemic immunity.
- This immunization strategy holds significant potential for the development of vaccines targeting mucosal pathogens.